• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病3年时的严重程度可根据基线时的非运动症状进行预测。

Parkinson's Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline.

作者信息

Ayala Alba, Triviño-Juárez José Matías, Forjaz Maria João, Rodríguez-Blázquez Carmen, Rojo-Abuin José-Manuel, Martínez-Martín Pablo

机构信息

Centre for Human and Social Sciences, Spanish Scientific Research Council (CCHS, CSIC) and Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain.

West Health District, Primary Care Center Francia, Madrid Health Service, Madrid, Spain.

出版信息

Front Neurol. 2017 Oct 30;8:551. doi: 10.3389/fneur.2017.00551. eCollection 2017.

DOI:10.3389/fneur.2017.00551
PMID:29163328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5674937/
Abstract

OBJECTIVE

The aim of this study is to present a predictive model of Parkinson's disease (PD) global severity, measured with the Clinical Impression of Severity Index for Parkinson's Disease (CISI-PD).

METHODS

This is an observational, longitudinal study with annual follow-up assessments over 3 years (four time points). A multilevel analysis and multiple imputation techniques were performed to generate a predictive model that estimates changes in the CISI-PD at 1, 2, and 3 years.

RESULTS

The clinical state of patients (CISI-PD) significantly worsened in the 3-year follow-up. However, this change was of small magnitude (effect size: 0.44). The following baseline variables were significant predictors of the global severity change: baseline global severity of disease, levodopa equivalent dose, depression and anxiety symptoms, autonomic dysfunction, and cognitive state. The goodness-of-fit of the model was adequate, and the sensitive analysis showed that the data imputation method applied was suitable.

CONCLUSION

Disease progression depends more on the individual's baseline characteristics than on the 3-year time period. Results may contribute to a better understanding of the evolution of PD including the non-motor manifestations of the disease.

摘要

目的

本研究旨在呈现一种帕金森病(PD)整体严重程度的预测模型,该模型通过帕金森病严重程度临床印象指数(CISI-PD)进行衡量。

方法

这是一项观察性纵向研究,进行了为期3年的年度随访评估(四个时间点)。采用多水平分析和多重填补技术生成一个预测模型,以估计1年、2年和3年时CISI-PD的变化。

结果

在3年的随访中,患者的临床状态(CISI-PD)显著恶化。然而,这种变化幅度较小(效应量:0.44)。以下基线变量是整体严重程度变化的显著预测因素:疾病的基线整体严重程度、左旋多巴等效剂量、抑郁和焦虑症状、自主神经功能障碍以及认知状态。模型的拟合优度良好,敏感性分析表明所应用的数据填补方法是合适的。

结论

疾病进展更多地取决于个体基线特征,而非3年的时间段。研究结果可能有助于更好地理解帕金森病的演变,包括该疾病的非运动表现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40b/5674937/a784866bed63/fneur-08-00551-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40b/5674937/342f1ad86e45/fneur-08-00551-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40b/5674937/a784866bed63/fneur-08-00551-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40b/5674937/342f1ad86e45/fneur-08-00551-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40b/5674937/a784866bed63/fneur-08-00551-g002.jpg

相似文献

1
Parkinson's Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline.帕金森病3年时的严重程度可根据基线时的非运动症状进行预测。
Front Neurol. 2017 Oct 30;8:551. doi: 10.3389/fneur.2017.00551. eCollection 2017.
2
Analysis of four scales for global severity evaluation in Parkinson's disease.帕金森病整体严重程度评估的四种量表分析
NPJ Parkinsons Dis. 2016 May 5;2:16007. doi: 10.1038/npjparkd.2016.7. eCollection 2016.
3
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life.帕金森病严重程度指数的临床印象及其与健康相关生活质量的关联。
Mov Disord Clin Pract. 2023 Jan 20;10(3):392-398. doi: 10.1002/mdc3.13649. eCollection 2023 Mar.
4
Global versus factor-related impression of severity in Parkinson's disease: a new clinimetric index (CISI-PD).帕金森病严重程度的整体与因素相关印象:一种新的临床测量指标(CISI-PD)
Mov Disord. 2006 Feb;21(2):208-14. doi: 10.1002/mds.20697.
5
The Clinical Impression of Severity Index for Parkinson's Disease: international validation study.帕金森病严重程度指数的临床印象:国际验证研究。
Mov Disord. 2009 Jan 30;24(2):211-7. doi: 10.1002/mds.22320.
6
Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.帕金森病患者接受双侧丘脑底核刺激 24 个月期间的非运动症状演变。
Mov Disord. 2018 Mar;33(3):421-430. doi: 10.1002/mds.27283. Epub 2018 Feb 21.
7
COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.COPPADIS - 2015(2015年西班牙帕金森病患者队列研究),一项关于帕金森病进展的全球性前瞻性、多中心、非干预性长期研究,涵盖临床评估、血清生物标志物、基因研究和神经影像学。
BMC Neurol. 2016 Feb 25;16:26. doi: 10.1186/s12883-016-0548-9.
8
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.新诊断帕金森病患者运动进展的临床和遗传预测因素的大规模识别:一项纵向队列研究及验证
Lancet Neurol. 2017 Nov;16(11):908-916. doi: 10.1016/S1474-4422(17)30328-9. Epub 2017 Sep 25.
9
Prognostic factors of Rapid symptoms progression in patients with newly diagnosed parkinson's disease.新发帕金森病患者快速症状进展的预后因素。
Artif Intell Med. 2020 Mar;103:101807. doi: 10.1016/j.artmed.2020.101807. Epub 2020 Jan 21.
10
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.帕金森病运动症状的自然史和左旋多巴的长期反应。
Brain. 2020 Aug 1;143(8):2490-2501. doi: 10.1093/brain/awaa181.

引用本文的文献

1
Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis.帕金森病运动进展率:一项系统评价与荟萃分析
Front Neurol. 2024 Sep 26;15:1452741. doi: 10.3389/fneur.2024.1452741. eCollection 2024.
2
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life.帕金森病严重程度指数的临床印象及其与健康相关生活质量的关联。
Mov Disord Clin Pract. 2023 Jan 20;10(3):392-398. doi: 10.1002/mdc3.13649. eCollection 2023 Mar.
3
SIALORRHEA AND XEROSTOMIA IN PARKINSON'S DISEASE PATIENTS.

本文引用的文献

1
Analysis of four scales for global severity evaluation in Parkinson's disease.帕金森病整体严重程度评估的四种量表分析
NPJ Parkinsons Dis. 2016 May 5;2:16007. doi: 10.1038/npjparkd.2016.7. eCollection 2016.
2
Bias and Precision of the "Multiple Imputation, Then Deletion" Method for Dealing With Missing Outcome Data.处理缺失结局数据的“多次插补,然后删除”方法的偏倚和精密度
Am J Epidemiol. 2015 Sep 15;182(6):528-34. doi: 10.1093/aje/kwv100. Epub 2015 Sep 2.
3
Using multiple imputation to deal with missing data and attrition in longitudinal studies with repeated measures of patient-reported outcomes.
口干和流涎在帕金森病患者中。
Acta Clin Croat. 2022 Aug;61(2):320-326. doi: 10.20471/acc.2022.61.02.19.
4
Low skull bone density is associated with poor motor prognosis in women with Parkinson's disease.低颅骨骨密度与帕金森病女性患者不良运动预后相关。
Front Aging Neurosci. 2022 Nov 15;14:1053786. doi: 10.3389/fnagi.2022.1053786. eCollection 2022.
5
Impact of Isolation During the COVID-19 Pandemic on the Patient Burden of Parkinson's Disease: A PMD Alliance Survey.2019年冠状病毒病大流行期间隔离对帕金森病患者负担的影响:一项帕金森病和运动障碍联盟调查
Neuropsychiatr Dis Treat. 2022 Mar 23;18:633-643. doi: 10.2147/NDT.S351691. eCollection 2022.
6
Baseline predictors of progression of Parkinson's disease in a sample of Egyptian patients: clinical and biochemical.埃及帕金森病患者样本中疾病进展的基线预测因素:临床和生化因素
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):9. doi: 10.1186/s41983-022-00445-1. Epub 2022 Jan 15.
7
Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.α-突触核蛋白作为帕金森病的生物标志物:有作用,但还不够。
Front Aging Neurosci. 2021 Jul 8;13:702639. doi: 10.3389/fnagi.2021.702639. eCollection 2021.
8
Evolution of Quality of Life in Persons with Parkinson's Disease: A Prospective Cohort Study.帕金森病患者生活质量的演变:一项前瞻性队列研究。
J Clin Med. 2021 Apr 22;10(9):1824. doi: 10.3390/jcm10091824.
9
Sicca Symptoms in Parkinson's Disease: Association with Other Nonmotor Symptoms and Health-Related Quality of Life.帕金森病中的口干症状:与其他非运动症状及健康相关生活质量的关联
Parkinsons Dis. 2020 Feb 12;2020:2958635. doi: 10.1155/2020/2958635. eCollection 2020.
10
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.突触可塑性与左旋多巴诱导的运动障碍:电生理学和结构异常。
J Neural Transm (Vienna). 2018 Aug;125(8):1263-1271. doi: 10.1007/s00702-018-1864-6. Epub 2018 Feb 28.
使用多重插补处理具有患者报告结局重复测量的纵向研究中的缺失数据和流失。
Clin Epidemiol. 2015 Jan 16;7:91-106. doi: 10.2147/CLEP.S72247. eCollection 2015.
4
Morbidity in early Parkinson's disease and prior to diagnosis.早期帕金森病及诊断前的发病率。
Brain Behav. 2014 May;4(3):446-52. doi: 10.1002/brb3.228. Epub 2014 Apr 8.
5
Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study.帕金森病的临床演变及影响运动进展的预后因素:9 年随访研究。
Eur J Neurol. 2015 Mar;22(3):457-63. doi: 10.1111/ene.12476. Epub 2014 Jun 2.
6
Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD.新诊断的帕金森病患者运动障碍、残疾和生活质量的预后因素。
Neurology. 2013 Feb 12;80(7):627-33. doi: 10.1212/WNL.0b013e318281cc99. Epub 2013 Jan 23.
7
The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life.帕金森病非运动症状的进展及其对运动障碍和生活质量的影响。
J Neurol. 2012 Dec;259(12):2621-31. doi: 10.1007/s00415-012-6557-8. Epub 2012 Jun 19.
8
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.疾病进展和治疗反应对帕金森病患者生存、残疾、认知障碍和抑郁的预测作用。
Br J Clin Pharmacol. 2012 Aug;74(2):284-95. doi: 10.1111/j.1365-2125.2012.04208.x.
9
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.帕金森病运动和非运动特征的进展及其对治疗的反应。
Br J Clin Pharmacol. 2012 Aug;74(2):267-83. doi: 10.1111/j.1365-2125.2012.04192.x.
10
[Influence of chronic health problems in dimensions of EQ-5D: study of institutionalized and non-institutionalized elderly].[慢性健康问题对EQ-5D维度的影响:对机构养老和非机构养老老年人的研究]
Rev Esp Salud Publica. 2011 Dec;85(6):555-68. doi: 10.1590/S1135-57272011120000005.